Patents Assigned to SIAMAB THERAPEUTICS, INC.
  • Glycan-interacting compounds and methods of use
    Patent number: 9879087
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: January 30, 2018
    Assignee: SIAMAB THERAPEUTICS, INC.
    Inventors: Julie DeSander, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
  • GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
    Publication number: 20160264684
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.
    Type: Application
    Filed: October 10, 2014
    Publication date: September 15, 2016
    Applicant: SIAMAB THERAPEUTICS, INC.
    Inventors: Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Intan Purnajo, Julie DeSander, Jeffrey Behrens
  • Compositions and methods for detecting cancer
    Patent number: 9423401
    Abstract: The invention provides sialylated glycans and antibodies that specifically bind to them. The invention's compositions and methods for using them are useful for early detection and diagnosis of cancer.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: August 23, 2016
    Assignees: The Regents of the University of California, Siamab Therapeutics, Inc.
    Inventors: Ajit Varki, Richard B. Schwab, Vered Padler-Karavani, Nancy Hurtado-Ziola
  • Glycan-interacting compounds
    Patent number: 9416194
    Abstract: The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 16, 2016
    Assignee: Siamab Therapeutics, Inc.
    Inventors: Darius Ghaderi, Ana Paula Galvao da Silva
  • Carbohydrate Compounds for Nutritional and Therapeutic Use
    Publication number: 20160106799
    Abstract: Embodiments of the present invention provide compositions and methods for the modulation of sialic acid levels. In some embodiments, compositions disclosed herein comprise nutraceuticals as functional agents.
    Type: Application
    Filed: May 29, 2014
    Publication date: April 21, 2016
    Applicant: SIAMAB THERAPEUTICS, INC.
    Inventors: Mai Zhang, Darius Ghaderi, Jeffrey Behrens, Julie DeSander, Ajit Varki
  • Glycan-interacting compounds
    Patent number: 9273142
    Abstract: The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: March 1, 2016
    Assignee: SIAMAB THERAPEUTICS, INC.
    Inventors: Darius Ghaderi, Ana Paula Galvao da Silva